Assuntos: DOENÇA DE CROHN, DOENÇAS AUTOIMUNES
ABNT
TEIXEIRA, Fábio Vieira et al. Serum levels of infliximab in Brazilian patients with Crohn's disease. [Comentário]: what are the reasons for differences from previous studies?. Clinics, v. 74, p. art. e1424 [2] , 2019Tradução . . Disponível em: https://doi.org/10.6061/clinics/2019/e1424. Acesso em: 16 nov. 2024.APA
Teixeira, F. V., Parra, R. S., Féres, O., & Kotze, P. G. (2019). Serum levels of infliximab in Brazilian patients with Crohn's disease. [Comentário]: what are the reasons for differences from previous studies? Clinics, 74, art. e1424 [2] . doi:10.6061/clinics/2019/e1424NLM
Teixeira FV, Parra RS, Féres O, Kotze PG. Serum levels of infliximab in Brazilian patients with Crohn's disease. [Comentário]: what are the reasons for differences from previous studies? [Internet]. Clinics. 2019 ; 74 art. e1424 [2] .[citado 2024 nov. 16 ] Available from: https://doi.org/10.6061/clinics/2019/e1424Vancouver
Teixeira FV, Parra RS, Féres O, Kotze PG. Serum levels of infliximab in Brazilian patients with Crohn's disease. [Comentário]: what are the reasons for differences from previous studies? [Internet]. Clinics. 2019 ; 74 art. e1424 [2] .[citado 2024 nov. 16 ] Available from: https://doi.org/10.6061/clinics/2019/e1424